Key result
Increased NF-κB-dependent MuRF1 expression accelerates BK-β1 subunit proteolysis, leading to impaired BK channel function and coronary vasodilation in diabetic models.
Why the study?
Does MuRF1 inhibition prevent BK channelopathy and vasculopathy in diabetic vessels?
Does MuRF1 inhibition prevent BK channelopathy and vasculopathy in diabetic vessels?
Up-regulation of NF-κB-dependent MuRF1 expression is a novel mechanism leading to BK channelopathy and vasculopathy in diabetes, suggesting MuRF1 as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
MuRF1 inhibition may preserve BK function in diabetic vessels; animal data leave open clinical translation.
The large conductance Ca(2+)-activated K(+) (BK) channel, expressed abundantly in vascular smooth muscle cells (SMCs), is a key determinant of vascular tone. BK channel activity is tightly regulated by its accessory β1 subunit (BK-β1). However, BK channel function is impaired in diabetic vessels by increased ubiquitin/proteasome-dependent BK-β1 protein degradation. Muscle RING finger protein 1 (MuRF1), a muscle-specific ubiquitin ligase, is implicated in many cardiac and skeletal muscle diseases. However, the role of MuRF1 in the regulation of vascular BK channel and coronary function has not been examined. In this study, we hypothesized that MuRF1 participated in BK-β1 proteolysis, leading to the down-regulation of BK channel activation and impaired coronary function in diabetes. Combining patch clamp and molecular biological approaches, we found that MuRF1 expression was enhanced, accompanied by reduced BK-β1 expression, in high glucose-cultured human coronary SMCs and in diabetic vessels. Knockdown of MuRF1 by siRNA in cultured human SMCs attenuated BK-β1 ubiquitination and increased BK-β1 expression, whereas adenoviral expression of MuRF1 in mouse coronary arteries reduced BK-β1 expression and diminished BK channel-mediated vasodilation. Physical interaction between the N terminus of BK-β1 and the coiled-coil domain of MuRF1 was demonstrated by pulldown assay. Moreover, MuRF1 expression was regulated by NF-κB. Most importantly, pharmacological inhibition of proteasome and NF-κB activities preserved BK-β1 expression and BK-channel-mediated coronary vasodilation in diabetic mice. Hence, our results provide the first evidence that the up-regulation of NF-κB-dependent MuRF1 expression is a novel mechanism that leads to BK channelopathy and vasculopathy in diabetes.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2014) studied Diabetic vasculopathy. MuRF1 modulation and pharmacological inhibition (MG132, TPCA-1) vs. Control (vehicle, normal glucose, or control siRNA) was evaluated on BK-β1 protein expression and BK channel-mediated vasodilation (p=<0.05). Increased NF-κB-dependent MuRF1 expression accelerates BK-β1 subunit proteolysis, leading to impaired BK channel function and coronary vasodilation in diabetic models.
Synapse has enriched 10 related papers. Consider them for comparative context: